ALX Oncology Holdings Inc
alxoncology.comWhat Do They Do?
Develops experimental cancer drug candidates for people with cancer, including a treatment that blocks a cancer-cell signal and an antibody-linked drug.
10-K for FY2025, filed Mar 9, 2026We are a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives.…View ↗
Anti-cancer agents, including many chemotherapies, other small molecules and anti-cancer antibodies, can stimulate immune cells such as…View ↗
Our second product candidate is ALX2004, a novel EGFR-targeted ADC. ALX2004 was created from our proprietary linker-payload library and…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$18MView ↗
- ▼ −31% (Loss)
- vs −$25.9M in Q2 FY2025
-
Jun 30, 2026
Corey Goodman resigned as chairman; Scott Garland succeeded him
Sources
8-K, filed Jun 30, 2026
On June 29, 2026, Corey Goodman, Ph.D. informed ALX Oncology Holdings Inc. (the “Company”) of his resignation as Chairman of the Company’s…View ↗
A broader drug pipeline
The pipeline has expanded beyond its lead immune-focused cancer drug candidate to include an antibody-linked cancer drug in clinical testing.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 9, 2026We are a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates…View ↗
Who Do They Compete With?
Competes with Adagene, Akesobio, Bio-Thera Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Byondis, Centessa, Conjupro Biotherapeutics, CTTQ (SinoBiological), Daiichi Sankyo, Exelixis, GenSci, Gilead Sciences, Hanchor Bio, Hisun, Hutchmed, I-Mab, Ichnos, ImmuneOncia Therapeutics, and ImmuneOnco Biopharma
10-K for FY2025, filed Mar 9, 2026Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach…View ↗
Loading...
